Simplex Trading
CTKB icon

Simplex Trading’s Cytek Biosciences CTKB Stock Holding History

Simplex Trading’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.21K Sell
500
-300
-38% -$1.28K ﹤0.01% 8596
2026
Q1 		$3.5K Sell
800
-800
-50% -$3.78K ﹤0.01% 8100
2025
Q4 		$8.08K Buy
+1,600
New +$7.43K ﹤0.01% 7129
2025
Q1 		– Sell
-900
Closed -$5K – 8673
2024
Q4 		$5K Buy
+900
New +$5.36K ﹤0.01% 7589
2023
Q4 		– Sell
-10,200
Closed -$56K – 8928
2023
Q3 		$56K Sell
10,200
-37,900
-79% -$304K ﹤0.01% 5697
2023
Q2 		$410K Buy
48,100
+10,100
+27% +$90.6K ﹤0.01% 3517
2023
Q1 		$349K Buy
38,000
+6,800
+22% +$73.1K ﹤0.01% 3652
2022
Q4 		$318K Sell
31,200
-4,600
-13% -$61.8K ﹤0.01% 3666
2022
Q3 		$526K Buy
+35,800
New +$465K ﹤0.01% 3405

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Simplex Trading's CTKB Position: Q2 2026 in Review

Simplex Trading sold out of Cytek Biosciences (CTKB) in Q2 2026, closing a stake of 3,226 shares — an estimated $13.8K sold.

Simplex Trading first reported a position in CTKB in Q4 2023 and held it in 9 quarters. The position peaked at $14.1K in Q1 2026. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Simplex Trading reported no remaining Cytek Biosciences position as of Q2 2026 after selling out during the quarter.
  • Simplex Trading sold 3,226 Cytek Biosciences shares in Q2 2026, an estimated $13.8K.
  • Simplex Trading first reported a position in Cytek Biosciences in Q4 2023 and held it in 9 quarters.
  • Simplex Trading's Cytek Biosciences position peaked at $14.1K in Q1 2026.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.